EP Patent

EP3824889A1 — Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of emotional lability

Assigned to Avanir Pharmaceuticals Inc · Expires 2021-05-26 · 5y expired

What this patent protects

Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.

USPTO Abstract

Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.

Drugs covered by this patent

dextromethorphan-hydrobromide (DEXTROMETHORPHAN HYDROBROMIDE)

Patent Metadata

Patent number: EP3824889A1
Jurisdiction: EP
Classification: —
Expires: 2021-05-26
Drug substance claim: No
Drug product claim: No
Assignee: Avanir Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.